NASDAQ:CNCE - Concert Pharmaceuticals, Inc.
$9.44
 $-0.40
-4.07%
4:00PM EDT
2019-04-18
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CNCE     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 51   203. 85   241. 91  
42 stocks rank:  3. 82 K 1. 44 K 1. 05 K
# analyst opinions:  6. 00   14. 51   13. 97  

quick ratio:  20. 28   5. 27   1. 81  
current ratio:  20. 59   5. 62   2. 25  

target price low:  13. 00   84. 80   115. 21  
target price avg:  19. 00   111. 51   137. 51  
target price high:  26. 00   135. 81   157. 84  
1-yr high:  20. 58   114. 23   138. 78  
last close:  9. 44   87. 66   116. 69  
50-day avg:  14. 02   95. 54   123. 44  
200-day avg:  14. 49   94. 25   121. 11  
1-yr low:  9. 44   72. 78   98. 34  
volume:  347. 81 K 4. 11 M 8. 07 M
50-day avg volume:  326. 28 K 2. 76 M 5. 02 M
200-day avg volume:  206. 89 K 2. 92 M 4. 59 M

1-day return:  -4. 07 % -0. 41 % 0. 07 %
this week return:  -6. 44 % -5. 74 % -4. 11 %
12-wk return:  -34. 94 % 1. 61 % -0. 05 %
52-wk return:  -47. 80 % 3. 12 % 8. 78 %

enterprise value (EV):  61. 28 M 48. 94 B 114. 64 B
market cap:  222. 12 M 43. 07 B 104. 73 B
EBITDA:  -54. 34 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -1. 13   4. 22   12. 73  
enterprise/revenue (EV/R):  5. 83   63. 17   12. 84  
total revenue:  10. 51 M 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -56. 02 M 2. 20 B 4. 20 B

shares outstanding:  23. 53 M 571. 70 M 1. 24 B
shares:  14. 58 M 571. 81 M 1. 23 B
shares short:  1. 20 M 10. 17 M 13. 00 M
shares short prior month:  1. 17 M 9. 54 M 17. 33 M
short ratio:  5. 14   5. 41   3. 28  
total cash/share:  6. 84   11. 14   9. 33  
total cash:  160. 84 M 6. 71 B 7. 15 B
free cash flow:  -39. 30 M 3. 58 B 2. 96 B
operating cash flow:  -48. 03 M 4. 15 B 4. 30 B

book value:  7. 16   12. 78   26. 92  
price/book:  1. 32   3. 06   -1. 74  
gross profits:  -32. 64 M 8. 04 B 34. 86 B
operating margins:  -529. 12 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -21. 61 % --- ---
1-yr mean volatility:  -0. 21 % 0. 03 % 0. 04 %

1-yr EPS:  -2. 40   2. 40   4. 10  
forward EPS:  -3. 59   3. 97   7. 13  
P/E:  -3. 93   13. 63   22. 72  
forward P/E:  -2. 63   -15. 95   13. 99  
PE/G:  -0. 13   -1. 65   -1. 32  
growth:  30. 00 % 127. 12 % 29. 61 %
earnings high:  -0. 05   1. 00   1. 66  
earnings avg:  -0. 70   0. 77   1. 53  
earnings low:  -0. 92   0. 50   1. 39  
revenue high:  16. 08 M 2. 68 B 10. 78 B
revenue avg:  5. 35 M 2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -17. 19 % -2. 75 % 4. 55 %
return on equity:  -30. 77 % -18. 45 % 5. 46 %
revenue growth:  30. 00 % 92. 86 % 18. 96 %
revenue/share:  0. 45   13. 29   55. 46  

beta (1yr vs S&P500):  1. 47   1. 25   0. 93  
sharpe (1yr):  -0. 85   0. 37   0. 70  

held % insiders:  10. 24 % 6. 39 % 3. 38 %
held % institutions:  86. 70 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : CNCE
.    + 0.672 =         0.672 :: INITIAL WEIGHT
.  + 111.657 =       112.329 :: inverse volume-to-price addition
.   + 45.594 =       157.923 :: spline projection addition
.    x 0.808 =       127.641 :: 13 weeks' performance factor
.    x 0.688 =        87.846 :: one-year gains+dividend factor
.    x 1.431 =       125.744 :: industry recommendation factor
.    x 1.092 =       137.354 :: EV/R factor
.    x 0.998 =       137.118 :: return on assets factor
.    x 0.997 =       136.697 :: return on equity factor
.    x 2.361 =       322.801 :: revenue growth factor
.      x 3.8 =      1226.544 :: current ratio factor
.    x 1.026 =      1257.954 :: quick ratio factor
.    x 1.093 =      1374.888 :: short ratio factor
.    x 2.013 =       2767.91 :: price-to-book factor
.    x 2.108 =      5833.416 :: P/E weight
.    x 1.662 =      9694.225 :: PE/G factor
.    x 1.505 =     14591.613 :: beta factor
.    x 0.845 =     12332.044 :: sharpe factor
.     x 1.65 =     20349.876 :: target low factor
.    x 1.335 =     27176.146 :: target mean factor
.    x 1.132 =     30775.562 :: target high factor
.     x 1.31 =     40312.536 :: industry 2-weeks return factor
.    x 0.993 =     40037.659 :: overall "drift" factor
.    x 0.999 =     40001.311 :: largest single-day jump factor
.    x 0.129 =      5168.128 :: low price factor
.      x 1.0 =      5167.289 :: factor hist industry gain for week 16
.   cubeRoot =        17.288 :: reduced to standardize
.   - 22.339 =         0.507 :: add/subtract for performance
.                      0.507 :: FINAL WEIGHT for NASDAQ:CNCE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org